Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7607226 | 1.00 | CA12 (0.54) | CA12CA14TSHRSMN1; SMN2TAS1R3 | |
| SCHEMBL28591466 | 0.87 | CA12 (0.47) | CA12CA14TSHRSMN1; SMN2TAS1R3 | |
| SCHEMBL28591468 | 0.87 | CA12 (0.47) | CA12CA14TSHRSMN1; SMN2TAS1R3 | |
| Benzene SCHEMBL27316296 | 0.87 | CA12 (0.43) | CA12CA14TSHRSMN1; SMN2TAS1R3 | |
| SCHEMBL22535026 | 0.86 | CA12 (0.41) | CA12CA14TSHRSMN1; SMN2TAS1R3 | |
| SCHEMBL15228353 | 0.85 | CA12 (0.48) | CA12CA14TSHRSMN1; SMN2TAS1R3 | |
| SCHEMBL21547821 | 0.85 | CA12 (0.39) | CA12CA14TSHRSMN1; SMN2TAS1R3 | |
| SCHEMBL23277649 | 0.84 | CA14 (0.42) | CA12CA14TSHRSMN1; SMN2TAS1R3 | |
| SCHEMBL16587941 | 0.83 | CA12 (0.47) | CA12CA14TSHRSMN1; SMN2TAS1R3 | |
| SCHEMBL25144944 | 0.83 | MAPT (0.40) | CA12CA14TSHRTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939814-B | Preparation method of deuterated dacarbazine intermediate | 正大天晴药业集团股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-9868745-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868745-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2900656-B1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| US-20150141326-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141326-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| WO-2014131315-A1 | BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014082380-A1 | FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-06-05 | — | — | WO | disclosed |
| US-8669234-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669234-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013021337-A1 | ANTIVIRAL COMPOUNDS WITH A FUSED TRICYCLIC RING | LUPIN LIMITED (IN) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013021344-A1 | IMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | LUPIN LIMITED (IN) | 2013-02-14 | — | — | WO | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2012087976-A2 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087976-A2 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2007084415-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CA12 4786/4885CA14 4775/4885TSHR 4333/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CA12 4309/4885CA14 3640/4885TSHR 4853/4885 |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CA12 4776/4885CA14 4768/4885TSHR 4331/4885 |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CA12 4776/4885CA14 4768/4885TSHR 4331/4885 |
| US-20150141326-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CA12 4026/4885CA14 3211/4885TSHR 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.